INB-100 is under clinical development by IN8bio and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I drugs for Myelodysplastic Syndrome have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how INB-100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
INB-100 is under development for the treatment of leukemia like acute and chronic myelocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome and lymphoma. The therapeutic candidate is administered through parenteral route. The therapeutic candidate is developed based on drug resistant immunotherapy (DRI) platform technology and consists of genetically modified gamma delta T cells administered along with chemotherapy.
IN8bio. is a clinical-stage biopharmaceutical firm focused on the development, marketing, and discovery of gamma-delta T cell therapeutics for cancer therapy. The company is headquartered in United States.
For a complete picture of INB-100’s drug-specific PTSR and LoA scores, buy the report here.